Letter Agreement for Extension of Collaborative Research Agreement between Pfizer Inc. and Xenogen Biosciences, Inc. (December 7, 2004)
Pfizer Inc. and Xenogen Biosciences, Inc. have agreed to extend their existing Collaborative Research Agreement, originally dated December 28, 2000, for one additional year. This extension is made under the terms of the original agreement and an amending letter from 2003. All other terms remain unchanged. The letter serves as formal notice of Pfizer's exercise of its first extension option, with additional extension options available in future years.
EXHIBIT 10.4
| | Groton Laboratories Pfizer Inc Eastern Point Road MS 8200-30 Groton, CT 06340 Tel ###-###-#### Fax ###-###-#### Email ***@*** | |
|
Global Research & Development | ||
| December 7, 2004 | Mark P. DellaPorta Senior Director Site Head, Groton Strategic Alliances | |
Dr. Stephen J. McAndrew
Xenogen Biosciences
5 Cedar Brook Drive
Cranbury, New Jersey 08512
Dear Dr. McAndrew,
Pursuant to Section 3.1(g) of the Collaborative Research Agreement dated December 28, 2000 (“2000 Agreement”) and the Amending Letter dated December 26, 2003 (“Amending Letter”) between Pfizer Inc (“Pfizer”) and Xenogen Biosciences (“Xenogen Cranbury”), Pfizer hereby exercises it’s option to extend the 2000 Agreement for one additional year. This Letter serves as notice of Pfizer’s exercise of the first extension only and while we note that there are three additional extension options available to Pfizer to exercise in subsequent years.
All other terms and conditions of the 2000 Agreement and the Amending Letter shall remain unchanged and in full force.
Please have the appropriate official of Xenogen Cranbury sign both copies of this Agreement and return one original to
Kelly P. Longo at the above address.
Sincerely,
| /s/ Mark P. DellaPorta |
| Mark P. DellaPorta |
| Site Director |
| Strategic Alliances |
Agreed:
Xenogen Biosciences, Inc.
| By: | /s/ Stephen J. McAndrew |  | ||||
| Date: | 12/10/04 | |||||
